{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/management/managing-complications/","result":{"pageContext":{"chapter":{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications","depth":2,"htmlHeader":"<!-- begin field d2236d89-5821-4086-9024-a79b00cf4437 --><h2>Scenario: Managing the major symptoms and complications of multiple sclerosis</h2><!-- end field d2236d89-5821-4086-9024-a79b00cf4437 -->","summary":"Covers the primary care management and referral of people with common complications of multiple sclerosis including fatigue, spasticity, ataxia, tremor, oscillopsia, mobility problems, mental health disorders, pain, sexual disorders, and bladder disorders.","htmlStringContent":"<!-- begin item 6dc58bb4-9fd5-43fd-bc83-a79b00cf41a9 --><!-- begin field d855058a-2a50-44cd-9da6-acbc0157523d --><p>From age 18 years onwards.</p><!-- end field d855058a-2a50-44cd-9da6-acbc0157523d --><!-- end item 6dc58bb4-9fd5-43fd-bc83-a79b00cf41a9 -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"bc409960-ced7-5028-a48d-0082f9c2b6c7","slug":"overview","fullItemName":"Overview","depth":3,"htmlHeader":"<!-- begin field 330ef93e-06b2-41e6-a45f-a79b00cf443c --><h3>Which complications should be managed in primary care?</h3><!-- end field 330ef93e-06b2-41e6-a45f-a79b00cf443c -->","summary":null,"htmlStringContent":"<!-- begin item da5e795d-7838-4fc2-9fa6-a79b00cf443c --><!-- begin field 7b182061-db7b-440c-b94e-a79b00cf443c --><ul><li class=\"MsoNormal\" style=\"line-height: normal;\"><strong>Many of the complications of multiple sclerosis are complex and will be managed by the specialist multidisciplinary team.</strong><ul><li>Liaison with members of the multidisciplinary team should be considered when taking decisions on management.</li><li>Depending on local arrangements and local guidelines, primary care practitioners may have a role to play in the management of a number of symptoms and complications including:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#fatigue\">Fatigue</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#spasticity\">Spasticity</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#ataxia-tremor\">Ataxia and tremor</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#oscillopsia\">Oscillopsia</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#mobility\">Mobility</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#mental-health\">Mental health</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#pain\">Pain</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#sexual-problems\">Sexual problems</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/management/managing-complications/#bladder-problems\">Bladder problems</a>.</li></ul></li></ul></li></ul><!-- end field 7b182061-db7b-440c-b94e-a79b00cf443c --><!-- end item da5e795d-7838-4fc2-9fa6-a79b00cf443c -->","subChapters":[]},{"id":"31946d83-2fa5-51c9-aa84-60c016736d18","slug":"fatigue","fullItemName":"Fatigue","depth":3,"htmlHeader":"<!-- begin field 041022e9-4673-4709-ad6d-a79b00df2693 --><h3>How should I manage fatigue in a person with multiple sclerosis?</h3><!-- end field 041022e9-4673-4709-ad6d-a79b00df2693 -->","summary":null,"htmlStringContent":"<!-- begin item ab1e576a-8918-4f88-85df-a79b00df224c --><!-- begin field 60179540-1a37-412b-a174-a79b00df2693 --><ul><li><strong>Assess the person for difficulty in sleeping, anxiety, depression, and other potential medical causes of tiredness such as anaemia and thyroid disease. </strong><ul><li>If identified, offer appropriate treatment.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tiredness-fatigue-in-adults/\">Tiredness/fatigue in adults</a>.</li></ul></li><li><strong>Explain that:</strong><ul><li>Multiple sclerosis (MS)-related fatigue is very common. Its cause is poorly understood and it may be precipitated by heat, overexertion, and stress — if possible, these factors should be minimized.</li><li>It may be helpful to plan each day ahead, to prioritize activities (saving energy for the more important or desired activities), and to take regular short rests during the day (rather than one long rest) — fatigue is likely to become worse as the day progresses.</li><li>Regular aerobic, balance, and stretching exercises including yoga may be helpful in easing MS-related fatigue.</li></ul></li><li><strong>Discuss further management with the person's MS team:</strong><ul><li><strong>Non-drug treatment (availability may vary locally) may be helpful and includes:</strong><ul><li>Mindfulness-based training.</li><li>Cognitive behavioural therapy.</li><li>Fatigue management educational programmes.</li><li>Supervised exercise programmes involving moderate progressive resistance training and aerobic exercise.</li><li>Vestibular rehabilitation for people with MS who have fatigue or mobility problems associated with limited standing balance.</li></ul></li><li><strong>The specialist team may consider drug treatments such as:</strong><ul><li>Amantadine (off-label indication) — may have a beneficial effect on MS-related fatigue. However, it is not effective in all people and may have intolerable adverse effects.</li></ul></li></ul></li></ul><!-- end field 60179540-1a37-412b-a174-a79b00df2693 --><!-- end item ab1e576a-8918-4f88-85df-a79b00df224c -->","subChapters":[{"id":"8eed938f-5f04-536e-ad73-19999d14d9f9","slug":"basis-for-recommendation-c83","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 88ca532d-3f52-49d9-ba5a-a79b00df2699 --><h4>Basis for recommendation</h4><!-- end field 88ca532d-3f52-49d9-ba5a-a79b00df2699 -->","summary":null,"htmlStringContent":"<!-- begin item c83b75e6-1080-4e62-bc86-a79b00df2699 --><!-- begin field 0610d7c3-b0d3-4430-8d02-a79b00df2699 --><h5>Assessing for other conditions, and offering information</h5><ul><li>The recommendation to assess for anxiety, depression, difficulty sleeping, and medical causes for a person with multiple sclerosis (MS) and fatigue, and to offer explanation and information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Veauthier, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</li></ul><h5>Considering a non-drug treatment</h5><p><strong> </strong></p><ul><li>The recommendation to consider the various non-drug interventions listed for MS-related fatigue is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Asano, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Cruickshank, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Veauthier, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</li><li>CKS recognizes that certain non-drug treatments may not be available in certain areas and therefore recommends that the choice should be based on local availability.</li></ul><h5>Drug treatment</h5><ul><li>NICE recommends consideration of amantadine as a drug treatment (based on very low to moderate quality evidence) as an option for MS-related fatigue [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><li>Amantadine is off-label for this indication.</li><li>A meta-analysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Asano, 2014</a>] concluded that evidence to support amantadine is weak, and that non-drug interventions seem to have a stronger and more significant effect on fatigue than amantadine.</li><li>The NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] states 'It is possible that pharmacological and non-pharmacological methods may influence different aspects of fatigue, and so their combined use may be complementary'.</li></ul><!-- end field 0610d7c3-b0d3-4430-8d02-a79b00df2699 --><!-- end item c83b75e6-1080-4e62-bc86-a79b00df2699 -->","subChapters":[]}]},{"id":"e5aa6ba2-1ec7-56e2-83ba-11e048ffb229","slug":"spasticity","fullItemName":"Spasticity","depth":3,"htmlHeader":"<!-- begin field 99425804-f41f-4f5d-a088-a79b00df4a77 --><h3>How should I manage spasticity in a person with multiple sclerosis?</h3><!-- end field 99425804-f41f-4f5d-a088-a79b00df4a77 -->","summary":null,"htmlStringContent":"<!-- begin item 5e129af4-f128-40ce-80c2-a79b00df4752 --><!-- begin field 08182ef4-66c9-4c74-aab1-a79b00df4a77 --><ul><li><strong>Assess for, and treat if possible, factors that may aggravate spasticity or trigger spasms.</strong><ul><li>These include: skin irritation, certain patterns of movement or posture, constipation, urinary tract or other infections, inappropriately fitted mobility aids, pressure ulcers, and pain. The person may be aware of other triggers pertinent to themselves.</li></ul></li><li><strong>Discuss with the person’s specialist team drug-treatment:</strong><ul><li>Baclofen or gabapentin (off-label) — may be recommended as a first-line drug treatment. <ul><li>The choice may depend on comorbidities, drug interactions, contraindications, and the person's preference. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/prescribing-information/\">Prescribing</a> for further information.</li><li>If the person cannot tolerate one of these, consider switching to the other.</li><li>Ensure the person has tried a drug at an optimal dose or the maximum dose they can tolerate to assess effect.</li><li>Stop the drug if there is no benefit at the maximum tolerated dose.</li></ul></li><li>The specialist team may consider tizanidine or dantrolene as a second-line drug treatment or a benzodiazepine as a third-line drug treatment.<ul><li>Daytime use of benzodiazepine is limited by sedative adverse effects but if taken at bedtime may be useful in easing nocturnal spasms.</li></ul></li></ul></li><li><strong>Ensure drug treatments are regularly reviewed.</strong></li><li><strong>Encourage the person to manage their own spasticity symptoms by explaining how doses of drugs can be adjusted within agreed limits.</strong></li><li><strong>Consider referral to physiotherapy.</strong><ul><li>Often a multidisciplinary approach is needed — assessment and advice on posture, positioning, standing, and splinting, may be helpful.</li></ul></li><li><strong>Ensure the person has been referred to a specialist spasticity service if the above measures are insufficient to control symptoms.</strong></li></ul><!-- end field 08182ef4-66c9-4c74-aab1-a79b00df4a77 --><!-- end item 5e129af4-f128-40ce-80c2-a79b00df4752 -->","subChapters":[{"id":"1dd2caed-4fd9-5102-a72d-e0d90ab9dcdc","slug":"basis-for-recommendation-f56","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6046ae38-2aa8-4ec3-ab84-a79b00df4a7c --><h4>Basis for recommendation</h4><!-- end field 6046ae38-2aa8-4ec3-ab84-a79b00df4a7c -->","summary":null,"htmlStringContent":"<!-- begin item f56c043f-419d-4e1d-9d52-a79b00df4a7c --><!-- begin field 0b4ef3ae-4ab8-4369-a637-a79b00df4a7c --><h5>Assessing for aggravating factors</h5><ul><li>The recommendation to assess for, and treat if possible, factors that may aggravate spasticity or trigger spasms is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].  </li></ul><h5>Drug treatment</h5><ul><li>Recommendations on drug treatments for multiple sclerosis (MS)-related spasticity or spasms are based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].<ul><li>Baclofen and gabapentin — the NICE guideline development group (GDG) chose baclofen as first-line therapy in view of cost, tolerability, and effectiveness seen in placebo-controlled trials and comparative trials, in addition to there being considerable experience among people with MS and professionals in using baclofen. The GDG acknowledged that the available trials showed that gabapentin had the clearest clinical benefits, but had more risk of adverse effects than baclofen. However, as gabapentin is also used for neuropathic pain, it may be a better option for people with spasticity and neuropathic pain. A combination of baclofen and gabapentin may be considered if one drug alone does not provide adequate relief of symptoms or if adverse effects prevent the dose of one drug being increased but caution should be exercised.</li><li>Suggested second- (tizanidine or dantrolene) and third-line drug treatments (a benzodiazepine) for MS-related spasticity or spasms are based on the NICE guideline.</li></ul></li><li>The European Academy of Neurology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Solari, 2020</a>] suggest oral baclofen (weak recommendation/very low certainty evidence) and tizanidine (weak recommendation/low certainty evidence) to reduce spasticity in patients with severe MS) once other symptoms and possible adverse events have been considered.</li></ul><h5>Encouraging the person to manage their own spasticity symptoms</h5><ul><li>The recommendation to encourage the person to manage their own spasticity symptoms by adjusting drug dosages within agreed limits is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><li>The NICE GDG considered that people with MS need to be empowered in their use of drugs to treat spasticity — experience of spasticity may differ between individuals and appropriate timing of treatment of spasticity may vary according to each individual’s lifestyle, commitments, and management of activities of daily living. Some people may require permission and encouragement to adjust their dose according to their needs, and people may need to take more than one drug at doses they can tolerate. Experience of people not being given adequate doses of drugs and also of remaining on drugs that they did not find useful for prolonged periods of time was noted.</li></ul><h5>Referral for physiotherapy</h5><ul><li>The recommendation to consider referral for physiotherapy for some people with MS is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li></ul><h5>Referral to a specialist spasticity service</h5><ul><li>The recommendation to refer to a specialist spasticity service if initial measures are not sufficient to ease spasticity symptoms is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><li>The NICE GDG describe a specialist spasticity service as consisting of a multidisciplinary outpatient service. Interventions may include advice on posture and positioning, customized seating, splinting, and standing as well a drug review, intramuscular botulinum toxin, or phenol injections. People are referred to this service when their needs cannot be addressed by local services, that is, when they have been unresponsive to pharmacological or therapeutic interventions and when their spasticity, spasms, or pain continue to cause difficulties affecting independence, carer burden, or quality of life.</li></ul><!-- end field 0b4ef3ae-4ab8-4369-a637-a79b00df4a7c --><!-- end item f56c043f-419d-4e1d-9d52-a79b00df4a7c -->","subChapters":[]}]},{"id":"1254e776-9cf1-583f-810d-02e5ce7b6791","slug":"ataxia-tremor","fullItemName":"Ataxia and tremor","depth":3,"htmlHeader":"<!-- begin field 70aa5c74-1a30-4a1c-bb38-a79b00df68c0 --><h3>How should I manage ataxia or tremor in a person with multiple sclerosis?</h3><!-- end field 70aa5c74-1a30-4a1c-bb38-a79b00df68c0 -->","summary":null,"htmlStringContent":"<!-- begin item 2a129a43-2520-4f24-af5d-a79b00df65f7 --><!-- begin field 605558b2-8c47-4e77-9085-a79b00df68c0 --><ul><li><strong>No specific treatment is currently recommended for multiple sclerosis (MS)-related tremor or ataxia.</strong></li><li><strong>Discuss options with the specialist team and consider offering referral to:</strong><ul><li>A physiotherapist with experience in MS for advice on such things as posture, and the best ways to cope with tremor.</li><li>An occupational therapist for advice on adaptions that can help if tremor affects activities of daily living. For example, aids for eating and drinking, assistive technology such as keyboard modifications, or voice activation for using a computer.</li></ul></li></ul><!-- end field 605558b2-8c47-4e77-9085-a79b00df68c0 --><!-- end item 2a129a43-2520-4f24-af5d-a79b00df65f7 -->","subChapters":[{"id":"0e6f1e13-baf1-5cb2-8378-c3720959816e","slug":"basis-for-recommendation-4b2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 09c24023-6eab-49fe-b608-a79b00df68c0 --><h4>Basis for recommendation</h4><!-- end field 09c24023-6eab-49fe-b608-a79b00df68c0 -->","summary":null,"htmlStringContent":"<!-- begin item 4b208f38-c5e4-4a4f-998e-a79b00df68c0 --><!-- begin field dd2f25ca-7da3-4139-a778-a79b00df68c0 --><h5>No treatment recommended for multiple sclerosis (MS)-related tremor or ataxia</h5><ul><li>The assertion that no treatment is recommended for MS-related ataxia or tremor is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>]. The guideline development group, having reviewed various studies relating to potential treatments, concluded that there was insufficient evidence to recommend any specific treatment.</li><li>Many drug treatments (such as propranolol, isoniazid, botulinum toxin, and clonazepam) have been tried for tremor in MS — adverse effects can be severe and evidence of effectiveness is very limited [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</li></ul><h5>Referral to physiotherapy and occupational therapy</h5><ul><li>CKS acknowledges that physiotherapy or occupational therapy are not recommended treatments to reverse or stop ataxia or tremor, but this recommendation is pragmatic based on the assumption that practitioners are experienced in being able to offer advice to people as to how best to cope and manage with these complications.</li></ul><!-- end field dd2f25ca-7da3-4139-a778-a79b00df68c0 --><!-- end item 4b208f38-c5e4-4a4f-998e-a79b00df68c0 -->","subChapters":[]}]},{"id":"9e5b7c89-10a3-5983-86c6-855ac2b27aa5","slug":"oscillopsia","fullItemName":"Oscillopsia","depth":3,"htmlHeader":"<!-- begin field 016ee574-93d6-44f0-828f-a79b00df89a7 --><h3>How should I manage oscillopsia in a person with multiple sclerosis?</h3><!-- end field 016ee574-93d6-44f0-828f-a79b00df89a7 -->","summary":null,"htmlStringContent":"<!-- begin item f1daf766-76ce-4142-b09e-a79b00df862d --><!-- begin field fd85c1eb-0a00-4159-94d4-a79b00df89a7 --><ul><li><strong>Oscillopsia can cause significant distress and functional limitation. </strong></li><li><strong>Discuss treatment options with the multiple sclerosis specialist team who may try:</strong><ul><li>Gabapentin (off-label) as a first-line drug treatment.</li><li>Memantine (off-label) as a second-line drug treatment.</li></ul></li><li><strong>If initial drug treatment fails or adverse effects prevent continued use, ensure the person is referred to a neuro-opthalmologist</strong>.</li></ul><!-- end field fd85c1eb-0a00-4159-94d4-a79b00df89a7 --><!-- end item f1daf766-76ce-4142-b09e-a79b00df862d -->","subChapters":[{"id":"6d2b5705-efc7-5f87-9dc8-e4b9c2d902a9","slug":"basis-for-recommendation-372","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c97f5c73-3990-42af-9668-a79b00df89ac --><h4>Basis for recommendation</h4><!-- end field c97f5c73-3990-42af-9668-a79b00df89ac -->","summary":null,"htmlStringContent":"<!-- begin item 3721c2d5-9d2d-4a20-a239-a79b00df89ac --><!-- begin field 661dd0bf-93f1-40b6-8c0a-a79b00df89ac --><p>The recommendations relating to the first- and second-line drug treatments and referral for a person with multiple sclerosis-related oscillopsia is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</p><ul><li>The guideline development group (GDG) acknowledged that the evidence base for treating oscillopsia is poor as their recommendations were based on only five small crossover interventional trials, with the largest study including only 15 participants. However, their conclusion was that a trial of treatment is appropriate for this condition.</li></ul><!-- end field 661dd0bf-93f1-40b6-8c0a-a79b00df89ac --><!-- end item 3721c2d5-9d2d-4a20-a239-a79b00df89ac -->","subChapters":[]}]},{"id":"c19059d8-a38c-564d-befd-9d95144cfb31","slug":"mobility","fullItemName":"Mobility","depth":3,"htmlHeader":"<!-- begin field f56fe8be-9170-41d3-bfff-a79b00df9e45 --><h3>How should I manage mobility problems in a person with multiple sclerosis?</h3><!-- end field f56fe8be-9170-41d3-bfff-a79b00df9e45 -->","summary":null,"htmlStringContent":"<!-- begin item 633d966c-6234-4d7b-80e6-a79b00df9bb2 --><!-- begin field f755a6a3-0a13-4d75-900d-a79b00df9e45 --><ul><li><strong>Assess for, and treat if possible, factors that may aggravate reduced mobility in a person with multiple sclerosis (MS) such as fatigue, spasticity, and visual problems.</strong></li><li><strong>Refer people with MS-related mobility problems for an assessment</strong> — this is usually to rehabilitation specialists and physiotherapists with expertise in MS who will consider, on an individual basis, the need for:<ul><li>Supervised exercise programmes involving moderate progressive resistance training and aerobic exercise.</li><li>Vestibular rehabilitation, especially for people with MS with limited standing balance.</li><li>Appropriate mobility aids.</li><li>Home adaptations such as stair lifts, transfer aids, or railings.</li></ul></li><li><strong>Encourage the person with MS to keep exercising after any specific exercise treatment programme ends.</strong></li></ul><!-- end field f755a6a3-0a13-4d75-900d-a79b00df9e45 --><!-- end item 633d966c-6234-4d7b-80e6-a79b00df9bb2 -->","subChapters":[{"id":"42017ad6-08b7-58a9-b9e1-ce75131a689e","slug":"basis-for-recommendation-b87","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 732dc0ea-0801-4898-80bb-a79b00df9e49 --><h4>Basis for recommendation</h4><!-- end field 732dc0ea-0801-4898-80bb-a79b00df9e49 -->","summary":null,"htmlStringContent":"<!-- begin item b87c6052-1d24-4ca3-a905-a79b00df9e49 --><!-- begin field 579ccde6-dc3a-4c07-8316-a79b00df9e49 --><h5>Assessing for aggravating factors</h5><ul><li>The recommendation to assess for factors that may aggravate reduced mobility in a person with multiple sclerosis (MS) is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Referring for an assessment</h5><ul><li>The recommendation to refer people with MS-related mobility problems for assessment with a view to considering a supervised exercise programme is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Halabchi, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Kalb, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li></ul><h5>Encouraging to continue exercising</h5><ul><li>The recommendation to encourage people with MS to continue exercising after any specific exercise treatment programme ends is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Halabchi, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Kalb, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li></ul><!-- end field 579ccde6-dc3a-4c07-8316-a79b00df9e49 --><!-- end item b87c6052-1d24-4ca3-a905-a79b00df9e49 -->","subChapters":[]}]},{"id":"5e460d24-3cc7-51ef-8c32-5222fdcf3c16","slug":"mental-health","fullItemName":"Mental health","depth":3,"htmlHeader":"<!-- begin field 55ae31e7-52c6-4b4b-b1ff-a79b00dfb464 --><h3>How should I manage multiple sclerosis-related mental health problems?</h3><!-- end field 55ae31e7-52c6-4b4b-b1ff-a79b00dfb464 -->","summary":null,"htmlStringContent":"<!-- begin item 0b9c8060-82a2-4d98-8178-a79b00dfb1e2 --><!-- begin field 6a5ff0fd-5e79-4798-974b-a79b00dfb464 --><ul><li><strong>For mental health disorders such as depression and anxiety:</strong><ul><li>Assess and manage as usual taking into account interactions and side effects of specific medications; some antidepressants can exacerbate multiple sclerosis (MS) symptoms such as cognitive impairment and fatigue — discuss with a specialist if unsure.</li><li>Consider offering cognitive behaviour therapy (CBT) for a person finding it difficult to adjust to, and cope with, having MS.</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>, <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder</a>, <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/psychosis-schizophrenia/\">Psychosis and schizophrenia</a>.</li></ul></li><li><strong>For MS-related emotional lability:</strong><ul><li>Discuss with the specialist team who may consider offering amitriptyline (off-label indication).</li></ul></li><li><strong>For cognitive problems:</strong><ul><li>Be aware that:<ul><li>A person with MS-related cognitive problems may not associate their cognitive problems as being due to their MS.</li><li>Anxiety, depression, difficulty in sleeping, and fatigue can impact on cognitive problems. If any of these are present then treatment, where possible, may improve cognitive problems.</li></ul></li><li>Refer people with MS and persisting memory or cognitive problems to both an occupational therapist and a neuropsychologist for assessment and management.</li></ul></li></ul><!-- end field 6a5ff0fd-5e79-4798-974b-a79b00dfb464 --><!-- end item 0b9c8060-82a2-4d98-8178-a79b00dfb1e2 -->","subChapters":[{"id":"950c43f2-f781-56ce-9162-2c25564a82de","slug":"basis-for-recommendation-88d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 09152b64-458b-4a81-aba2-a79b00dfb469 --><h4>Basis for recommendation</h4><!-- end field 09152b64-458b-4a81-aba2-a79b00dfb469 -->","summary":null,"htmlStringContent":"<!-- begin item 88d4e62c-f440-44aa-bcb4-a79b00dfb469 --><!-- begin field c51ef3c8-5f4e-467f-a23f-a79b00dfb469 --><h5>Mood disorders</h5><ul><li>Recommendations on management of mood disorders in people with multiple sclerosis (MS) are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>], the clinical practice guideline <em>Identification and management of depression in multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Alberta Health and the Alberta Medical Association, 2015</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li><li>A Cochrane review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thomas, 2006</a>] found reasonable evidence that cognitive behavioural approaches are beneficial in helping people adjust to, and cope with, having MS — this conclusion is in keeping with the NICE guideline on MS whose guideline development group (GDG) acknowledge that 'there can also be a role for psychological input in helping people come to terms with either the diagnosis of MS and/or the distress associated with physical and cognitive disability'.</li></ul><h5>Offering amitriptyline for emotional lability</h5><ul><li>The recommendation to consider offering amitriptyline to a person with MS-related emotional lability is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li><li>The NICE GDG acknowledged that there was very little evidence available from randomized controlled trials for this recommendation but considered that there is experience of the use of amitriptyline for emotional lability and that a trial of this is worthwhile. Also, that amitriptyline is a drug commonly used for a number of different medical problems and therefore neurologists and other healthcare professionals have a lot of experience in using it and of the adverse effects that can occur.</li></ul><h5>Managing cognitive problems</h5><ul><li>The recommendations relating to cognitive problems that may develop in a person with MS are based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>]<em> and expert opinion in a review article</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li></ul><!-- end field c51ef3c8-5f4e-467f-a23f-a79b00dfb469 --><!-- end item 88d4e62c-f440-44aa-bcb4-a79b00dfb469 -->","subChapters":[]}]},{"id":"84e81518-51c6-5dd1-a283-3acb4354e006","slug":"pain","fullItemName":"Pain","depth":3,"htmlHeader":"<!-- begin field aadc4d65-36f2-4cb2-abb8-a79b00dfc967 --><h3>How should I manage multiple sclerosis-related pain?</h3><!-- end field aadc4d65-36f2-4cb2-abb8-a79b00dfc967 -->","summary":null,"htmlStringContent":"<!-- begin item 5909cfc7-25ee-4146-afbd-a79b00dfc6dd --><!-- begin field de365cca-af10-4860-a09a-a79b00dfc967 --><ul><li><strong>Assess the person's pain bearing in mind that the origin of the pain may be neuropathic, musculoskeletal, or both.</strong><ul><li><strong>Musculoskeletal pain:</strong><ul><li>Musculoskeletal pain is common in people with MS and usually secondary to problems with mobility and posture.</li><li>Consider referring the person to physiotherapy if the pain seems to be related to poor mobility or poor posture, and there is a likelihood that physiotherapy will be able to improve these symptoms.</li><li>For further information on drug treatment, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> and <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul></li><li><strong>Neuropathic pain:</strong><ul><li>For further information on drug treatment, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a>.</li></ul></li></ul></li><li><strong>Refer to pain services, if appropriate.</strong></li></ul><!-- end field de365cca-af10-4860-a09a-a79b00dfc967 --><!-- end item 5909cfc7-25ee-4146-afbd-a79b00dfc6dd -->","subChapters":[{"id":"65e5b6c7-391f-526f-8c82-d75b11bb19f1","slug":"basis-for-recommendation-980","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 434a1a43-2eb6-4812-8d56-a79b00dfc971 --><h4>Basis for recommendation</h4><!-- end field 434a1a43-2eb6-4812-8d56-a79b00dfc971 -->","summary":null,"htmlStringContent":"<!-- begin item 980434f2-f6d4-47be-a938-a79b00dfc971 --><!-- begin field 8407119d-ea62-478c-8b75-a79b00dfc971 --><p>The recommendations relating to the management of pain in a person with multiple sclerosis are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</p><ul><li>The guideline states 'Treat neuropathic pain in people with MS according to <a href=\"https://www.nice.org.uk/Guidance/CG173\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"1658ccd3-86b0-4166-b95c-ac2c00d54090\">Neuropathic pain in adults: pharmacological management in non-specialist settings</a> (NICE clinical guideline 173) and refer to pain services if appropriate'. The CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> is based on the NICE neuropathic pain guideline.</li><li>The recommendation to refer to physiotherapy was considered pragmatic as NICE states that 'musculoskeletal pain is common in people with MS and is usually secondary to problems with mobility and posture ... assess musculoskeletal pain, offer treatment to the person and refer them as appropriate'.</li></ul><!-- end field 8407119d-ea62-478c-8b75-a79b00dfc971 --><!-- end item 980434f2-f6d4-47be-a938-a79b00dfc971 -->","subChapters":[]}]},{"id":"41cd4716-4b0d-55ca-9f4a-376703ae242b","slug":"sexual-problems","fullItemName":"Sexual problems","depth":3,"htmlHeader":"<!-- begin field 16c88a83-ddc5-4a72-868c-a79b00dfe5c3 --><h3>How should I manage sexual problems related to multiple sclerosis?</h3><!-- end field 16c88a83-ddc5-4a72-868c-a79b00dfe5c3 -->","summary":null,"htmlStringContent":"<!-- begin item 9b7006c7-acfe-4612-bbea-a79b00dfe23a --><!-- begin field 6a3d7922-f75a-486a-895f-a79b00dfe5c3 --><ul><li><strong>Be aware that sexual problems are common in people with multiple sclerosis (MS), but are often under reported and overlooked by healthcare professionals.</strong><ul><li>Carry out a thorough assessment.</li><li>Discuss with/refer to secondary care where appropriate.</li><li>Consider the need for medication in men with erectile dysfunction — for further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a>.</li></ul></li><li><strong>Consider offering referral for relationship counselling services (such as Relate) or for psychosexual counselling, where appropriate.</strong></li></ul><!-- end field 6a3d7922-f75a-486a-895f-a79b00dfe5c3 --><!-- end item 9b7006c7-acfe-4612-bbea-a79b00dfe23a -->","subChapters":[{"id":"53d7507d-6d01-59ab-a9f6-b3fc427c371a","slug":"basis-for-recommendation-378","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c713951b-6750-421b-a469-a79b00dfe5cd --><h4>Basis for recommendation</h4><!-- end field c713951b-6750-421b-a469-a79b00dfe5cd -->","summary":null,"htmlStringContent":"<!-- begin item 378fdff4-92f5-4777-84cb-a79b00dfe5cd --><!-- begin field 97614b3d-9e73-4cc7-b45d-a79b00dfe5cd --><p>Recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019b</a>].</p><ul><li>Sexual dysfunction can occur as a result of multiple sclerosis (MS) itself and/or drugs used in its treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019b</a>].</li><li>The recommendation to be aware that sexual problems are common but are often under reported in people with MS, and often overlooked by healthcare professionals, is based on a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Kessler, 2009</a>] that draws attention to this issue, and to the surveys [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Lew-Starowicz, 2013</a>] and [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Lew-Starowicz, 2014</a>] that highlight the very low percentage of people with MS and sexual problems who had discussed their sexual health concerns with a health professional (2.2% and 6%, and n = 137 and n = 67, respectively in these surveys).</li><li>The recommendation to consider offering referral to relationship counselling or psychosexual counselling, if appropriate, is pragmatic and considered by CKS to be good clinical practice.</li></ul><!-- end field 97614b3d-9e73-4cc7-b45d-a79b00dfe5cd --><!-- end item 378fdff4-92f5-4777-84cb-a79b00dfe5cd -->","subChapters":[]}]},{"id":"f53e0db6-1af7-599b-987e-3d052850f5b9","slug":"bladder-problems","fullItemName":"Bladder problems","depth":3,"htmlHeader":"<!-- begin field 14758fe5-00d7-41f5-b037-a79b00dffea9 --><h3>How should I manage lower urinary tract problems related to multiple sclerosis?</h3><!-- end field 14758fe5-00d7-41f5-b037-a79b00dffea9 -->","summary":null,"htmlStringContent":"<!-- begin item 9c63f30e-cf33-46ef-b2fe-a79b00dffc0c --><!-- begin field d42a7027-1a3b-4a78-afa6-a79b00dffea9 --><ul><li><strong>Management of urinary dysfunction in people with multiple sclerosis (MS) is complex</strong> — discuss with the MS team and refer where appropriate to urology, neurourology, or urogynaecology.<ul><li>For information on general management of lower urinary tract problems, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/luts-in-men/\">LUTS in men</a>, <a class=\"topic-reference external-reference\" href=\"/topics/incontinence-urinary-in-women/\">Incontinence - urinary, in women</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/urinary-tract-infection-lower-women/\">Urinary Tract Infection (lower) - women</a>.</li></ul></li></ul><!-- end field d42a7027-1a3b-4a78-afa6-a79b00dffea9 --><!-- end item 9c63f30e-cf33-46ef-b2fe-a79b00dffc0c -->","subChapters":[{"id":"76bbd118-1682-5a99-98b6-77d0e84edf42","slug":"basis-for-recommendation-685","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c6989fdc-2958-49cc-bed0-ac22008ec9d9 --><h4>Basis for recommendation</h4><!-- end field c6989fdc-2958-49cc-bed0-ac22008ec9d9 -->","summary":null,"htmlStringContent":"<!-- begin item 68528303-0052-4b23-9e4e-40f2d983c4e3 --><!-- begin field 80ed001b-7d0d-4688-b6d7-ac22008ec9d9 --><p>The recommendation to refer to secondary care for assessment and management of urinary dysfunction in people with multiple sclerosis is based on clinical guidance from the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Aharony, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</p><!-- end field 80ed001b-7d0d-4688-b6d7-ac22008ec9d9 --><!-- end item 68528303-0052-4b23-9e4e-40f2d983c4e3 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}